Journal of Neural Transmission

, Volume 119, Issue 7, pp 833–842

A novel ARC gene polymorphism is associated with reduced risk of Alzheimer’s disease

  • Sara Landgren
  • Malin von Otter
  • Mona Seibt Palmér
  • Caroline Zetterström
  • Staffan Nilsson
  • Ingmar Skoog
  • Deborah R. Gustafson
  • Lennart Minthon
  • Anders Wallin
  • Niels Andreasen
  • Nenad Bogdanovic
  • Jan Marcusson
  • Kaj Blennow
  • Henrik Zetterberg
  • Petronella Kettunen
Dementias - Original Article

DOI: 10.1007/s00702-012-0823-x

Cite this article as:
Landgren, S., von Otter, M., Palmér, M.S. et al. J Neural Transm (2012) 119: 833. doi:10.1007/s00702-012-0823-x

Abstract

Alzheimer’s disease (AD) is the most common neurodegenerative disease, and is clinically characterized by cognitive disturbances and the accumulation of the amyloid β (Aβ) peptides in plaques in the brain. Recent studies have shown the links between AD and the immediate-early gene Arc (activity-regulated cytoskeleton-associated protein), involved in synaptic plasticity and memory consolidation. For example, AD mouse models show a decreased expression of Arc mRNA in the brain. In additional, acute Aβ application to brain slices leads to a widespread ARC protein diffusion, unlike the normal defined localization to synapses. In this study, we investigated genetic variation in human ARC and the risk of developing AD. To this end, we genotyped 713 subjects diagnosed with AD and 841 controls without dementia. ARC was sequenced in a group of healthy individuals, and seven previously known SNPs and three novel SNPs were identified. Two of the newly found SNPs were intronic and one, +2852(G/A), was located in the 3′UTR. Three tag SNPs were selected, including the novel SNP +2852(G/A), to relate to risk of AD, Mini Mental State Examination (MMSE) scores and cerebrospinal fluid (CSF) biomarker levels of total tau (T-tau), hyperphosphorylated tau181 (P-tau181) and Aβ1–42. The AA genotype of the newly found 3′-UTR SNP +2852(A/G), was associated with a decreased risk of AD (pc = 0.005; OR = 0.74; 95 % CI: 0.61–0.89). No associations of single SNPs or haplotypes with MMSE score or CSF biomarkers were found. Here we report a novel ARC SNP associated with a reduced risk of developing AD. To our knowledge, this is the first study associating a gene variant of ARC with any disease. The location of the SNP within the 3′UTR indicates that dendritic targeting of ARC mRNA could be involved in the molecular mechanisms underlying this protective function. However, further investigation of the importance of this SNP for ARC function, ARC processing and the pathology of AD is needed.

Keywords

Activity-regulated cytoskeleton-associated proteinSingle nucleotide polymorphismGene associationAlzheimer’s diseaseMemoryImmediate-early gene

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Sara Landgren
    • 1
  • Malin von Otter
    • 2
  • Mona Seibt Palmér
    • 3
  • Caroline Zetterström
    • 2
  • Staffan Nilsson
    • 4
  • Ingmar Skoog
    • 2
  • Deborah R. Gustafson
    • 2
  • Lennart Minthon
    • 5
  • Anders Wallin
    • 2
  • Niels Andreasen
    • 6
  • Nenad Bogdanovic
    • 6
  • Jan Marcusson
    • 7
  • Kaj Blennow
    • 2
  • Henrik Zetterberg
    • 2
    • 8
  • Petronella Kettunen
    • 2
  1. 1.Department of Pharmacology, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of GothenburgGothenburgSweden
  2. 2.Department of Psychiatry and Neurochemistry, Institute of Neuroscience and PhysiologyThe Sahlgrenska Academy at the University of GothenburgGothenburgSweden
  3. 3.Department of Clinical Chemistry and Transfusion Medicine, Institute of BiomedicineThe Sahlgrenska Academy at the University of GothenburgGothenburgSweden
  4. 4.Department of Mathematical Statistics, Institute of Mathematical SciencesChalmers University of TechnologyGothenburgSweden
  5. 5.Department of Clinical SciencesClinical Memory Research Unit, Lund UniversityMalmöSweden
  6. 6.Division of Clinical Geriatrics, Department of Neurobiology, Caring Science and SocietyKarolinska InstitutetStockholmSweden
  7. 7.Department of Clinical and Experimental Medicine, Division of Geriatric MedicineLinköping UniversityLinköpingSweden
  8. 8.UCL Institute of NeurologyLondonUK